The Emperor's new clothes: PDE5 and the heart

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Degen, Chantal V ^a   Bishu, Kalkidan ^a   Zakeri, Rosita ^a   Ogut, Ozgur ^a   Redfield, Margaret M ^a   Brozovich, Frank V ^a  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; PHOSPHODIESTERASE V; AUTOANTIBODY;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTROPHORESIS; ENZYME ACTIVITY; HEART; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HUMAN; HUMAN TISSUE; LUNG; MALE; MIDDLE AGED; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CARDIAC MUSCLE; DOG; ENZYMOLOGY; FEMALE; IMMUNOLOGY; METABOLISM;

BOVINAE; CANIS FAMILIARIS; MURINAE;

ADULT; AGED; ANIMALS; AUTOANTIBODIES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DOGS; FEMALE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; MYOCARDIUM;

EID: 84924154230     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0118664     Document Type: Article

References (43)

1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Executive summary: heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation 2012; 125: 188-197. doi: 10.1161/CIR.0b013e3182456d46 PMID: 22215894
2. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62: e147-e239. doi: 10.1016/j.jacc.2013.05.019 PMID: 23747642
3. Francis GS, Cohn JN. Heart failure: mechanisms of cardiac and vascular dysfunction and the rationale for pharmacologic intervention. FASEB J 1990; 4: 3068-3075. PMID: 2210153
4. Chen HH, Lainchbury JG, Senni M, Bailey KR, Redfield MM. Diastolic heart failure in the community: clinical profile, natural history, therapy, and impact of proposed diagnostic criteria. J Cardiac Failure 2002; 8: 279-287. PMID: 12411978
5. Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, et al. Trends in heart failure incidence and survival in a community-based population. JAMA 2004; 292: 344-350. PMID: 15265849
6. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J 2011; 32: 670-679. doi: 10.1093/eurheartj/ehq426 PMID: 21138935
7. Takimoto E, Champion HC, Belardi D, Moslehi J, Mongillo M, Mergia E, et al. cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism. Circ Res 2005; 96: 100-109. PMID: 15576651
8. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005; 11: 214-222. PMID: 15665834
9. Takimoto E, Belardi D, Tocchetti CG, Vahebi S, Cormaci G, Ketner EA, et al. Compartmentalization of cardiac beta-adrenergic inotropy modulation by phosphodiesterase type 5. Circulation 2007; 115: 2159-2167. PMID: 17420342
10. Zhang M, Koitabashi N, Nagayama T, Rambaran R, Feng N, Takimoto E, et al. Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes. Cell Signal 2008; 20: 2231-2236. doi: 10.1016/j.cellsig.2008.08.012 PMID: 18790048
11. Lukowski R, Rybalkin SD, Loga F, Leiss V, Beavo JA, Hofmann F. Cardiac hypertrophy is not amplified by deletion of cGMP-dependent protein kinase I in cardiomyocytes. Proc Natl Acad Sci USA 2010; 107: 5646-5651. doi: 10.1073/pnas.1001360107 PMID: 20212138
12. Wallis RM, Corbin JD, Francis SH, Ellis P. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 1999; 83: 3C-12C. PMID: 10078537
13. Vandeput F, Krall J, Ockaili R, Salloum FN, Florio V, Corbin JD, et al. cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium. J Pharmacol Exp Ther 2009; 330: 884-891. doi: 10.1124/jpet.109.154468 PMID: 19546307
14. Miller CL, Oikawa M, Cai Y, Wojtovich AP, Nagel DJ, Xu X, et al. Role of Ca2+/calmodulin-stimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy. Circ Res 2009; 105: 956-964. doi: 10.1161/CIRCRESAHA.109.198515 PMID: 19797176
15. Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2013; 309: 1268-1277. doi: 10.1001/jama.2013.2024 PMID: 23478662
16. Andersen MJ, Ersbøll M, Axelsson A, Gustafsson F, Hassager C, Kober L, et al. Sildenafil and diastolic dysfunction after acute myocardial infarction in patients with preserved ejection fraction: the sildenafil and diastolic dysfunction after acute myocardial infarction (SIDAMI) trial. Circulation 2013; 127: 1200-1208. doi: 10.1161/CIRCULATIONAHA.112.000056 PMID: 23406672
17. Mohammed SF, Ohtani T, Korinek J, Lam CSP, Larsen K, Simari RD, et al. Mineralocorticoid accelerates transition to heart failure with preserved ejection fraction via "nongenomic effects". Circulation 2010; 122: 370-378. doi: 10.1161/CIRCULATIONAHA.109.915215 PMID: 20625113
18. Bishu K, Ogut O, Kushwaha S, Mohammed SF, Ohtani T, Xu X, et al. Anti-remodeling effects of rapamycin in experimental heart failure: dose response and interaction with angiotensin receptor blockade. PLoS ONE 2013; 8: e81325. doi: 10.1371/journal.pone.0081325 PMID: 24312548
19. Mohammed SF, Storlie JR, Oehler EA, Bowen LA, Korinek J, Lam CSP, et al. Variable phenotype in murine transverse aortic constriction. Cardiovasc Pathol 2012; 21: 188-198. doi: 10.1016/j.carpath. 2011.05.002 PMID: 21764606
20. Shapiro BP, Owan TE, Mohammed SF, Meyer DM, Mills LD, Schalkwijk CG, et al. Advanced glycation end products accumulate in vascular smooth muscle and modify vascular but not ventricular properties in elderly hypertensive canines. Circulation 2008; 118: 1002-1010. doi: 10.1161/CIRCULATIONAHA. 108.777326 PMID: 18711013
21. Shapiro BP, Lam CSP, Patel JB, Mohammed SF, Kruger M, Meyer DM, et al. Acute and chronic ventric-ular- arterial coupling in systole and diastole: insights from an elderly hypertensive model. Hypertension 2007; 50: 503-511. PMID: 17620524
22. Bishu K, Hamdani N, Mohammed SF, Krüger M, Ohtani T, Ogut O, et al. Sildenafil and B-Type Natriuretic Peptide Acutely Phosphorylate Titin and Improve Diastolic Distensibility In Vivo. Circulation 2011; 124: 2882-2891. doi: 10.1161/CIRCULATIONAHA.111.048520 PMID: 22144574
23. Hamdani N, Bishu KG, Frieling-Salewsky von M, Redfield MM, Linke WA. Deranged myofilament phosphorylation and function in experimental heart failure with preserved ejection fraction. Cardiovascular Research 2013; 97: 464-471. doi: 10.1093/cvr/cvs353 PMID: 23213108
24. Yuen SL, Ogut O, Brozovich FV. Nonmuscle myosin is regulated during smooth muscle contraction. Am J Phsiol: Heart Circ Physiol 2009; 297: H191-H199. doi: 10.1152/ajpheart.00132.2009 PMID: 19429828
25. Given AM, Ogut O, Brozovich FV. MYPT1 mutants demonstrate the importance of aa 888-928 for the interaction with PKGIalpha. Am J Physiol, Cell Physiol 2007; 292: C432-C439. PMID: 16870832
26. Rybalkin SD, Rybalkina IG, Feil R, Hofmann F, Beavo JA. Regulation of cGMP-specific phosphodiesterase (PDE5) phosphorylation in smooth muscle cells. J Biol Chem 2002; 277: 3310-3317. PMID: 11723116
27. Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A, et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 2007; 116: 238-248. PMID: 17606845
28. Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA. Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res 2003; 93: 280-291. PMID: 12933699
29. Patrucco E, Domes K, Sbroggió M, Blaich A, Schlossmann J, Desch M, et al. Roles of cGMP-dependent protein kinase I (cGKI) and PDE5 in the regulation of Ang II-induced cardiac hypertrophy and fibrosis. Proc Natl Acad Sci USA 2014; 111: 12925-12929. doi: 10.1073/pnas.1414364111 PMID: 25139994
30. Corbin JD, Beasley A, Blount MA, Francis SH. High lung PDE5: A strong basis for treating pulmonary hypertension with PDE5 inhibitors. Biochem Biophys Res Commun 2005; 334: 930-938. PMID: 16023993
31. Corbin J, Rannels S, Neal D, Chang P, Grimes K, Beasley A, et al. Sildenafil citrate does not affect cardiac contractility in human or dog heart. Curr Med Res Opin 2003; 19: 747-752. PMID: 14687446
32. Eghbali M, Czaja MJ, Zeydel M, Weiner FR, Zern MA, Seifter S, et al. Collagen chain mRNAs in isolated heart cells from young and adult rats. J Mol Cell Cardiol 1988; 20: 267-276. PMID: 3398057
33. Senzaki H, Smith CJ, Juang GJ, Isoda T, Mayer SP, Ohler A, et al. Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure. FASEB J 2001; 15: 1718-1726. PMID: 11481219
34. Shan X, Quaile MP, Monk JK, French B, Cappola TP, Margulies KB. Differential expression of PDE5 in failing and nonfailing human myocardium. Circ Heart Fail 2012; 5: 79-86. doi: 10.1161/ CIRCHEARTFAILURE.111.961706 PMID: 22135403
35. Pokreisz P, Vandenwijngaert S, Bito V, Van den Bergh A, Lenaerts I, Busch C, et al. Ventricular phos-phodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. Circulation 2009; 119: 408-416. doi: 10.1161/CIRCULATIONAHA.108.822072 PMID: 19139381
36. Lu Z, Xu X, Hu X, Lee S, Traverse JH, Zhu G, et al. Oxidative stress regulates left ventricular PDE5 expression in the failing heart. Circulation 2010; 121: 1474-1483. doi: 10.1161/CIRCULATIONAHA.109.906818 PMID: 20308615
37. Greenbaum D, Colangelo C, Williams K, Gerstein M. Comparing protein abundance and mRNA expression levels on a genomic scale. Genome Biol 2014; 4: 117.
38. Guazzi M, Vicenzi M, Arena R, Guazzi MD. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail 2011; 4: 8-17. doi: 10. 1161/CIRCHEARTFAILURE.110.944694 PMID: 21036891
39. Archer SL, Weir EK, Wilkins MR. Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation 2010; 121: 2045-2066. doi: 10.1161/CIRCULATIONAHA.108.847707 PMID: 20458021
40. McGoon M, Gutterman D, Steen V, Barst R, McCrory DC, Fortin TA, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126: 14S-34S. PMID: 15249493
41. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. JACC 2004; 43: 40S-47S. PMID: 15194177
42. Sitbon O, Humbert M, Jagot JL, Taravella O, Fartoukh M, Parent F, et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998; 12: 265-270. PMID: 9727772
43. Giannetta E, Isidori AM, Galea N, Carbone I, Mandosi E, Vizza CD, et al. Chronic Inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging. Circulation 2012; 125: 2323-2333. doi: 10.1161/CIRCULATIONAHA.111.063412 PMID: 22496161